menu

Achieving Long-Term Success in the Management of IBD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Achieving Long-Term Success in the Management of IBD

close
0.25 credits
15 minutes
Achieving Long-Term Success in the Management of IBD
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Neilanjan Nandi, MD, FACP, AGAF
    Associate Professor of Clinical Medicine
    University of Pennsylvania
    Penn Presbyterian Medical Center
    Philadelphia, PA 

    Consulting Fees: Forefront,Pfizer

    Faculty:
    Gary R. Lichtenstein, MD, FACG, FACP, AGAF
    Professor of Medicine
    Director, Center for Inflammatory Bowel Disease
    University of Pennsylvania Health System
    Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 

    Consulting Fees: AbbVie, American Regent, Celgene, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Ortho Biotech, Merck, Morphic Therapeutic, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, and UCB
    Contracted Research: Celgene, Janssen Ortho Biotech, and UCB; served on the DSMB for Eli Lilly
    Received Honoraria (CME program): American Regent, Merck, and Romark
    Received Funding to the University of Pennsylvania (IBD fellow education): Janssen Ortho Biotech, Pfizer Pharmaceuticals, and Takeda.

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Colleen Resnick has nothing to disclose.
    • Poonam Kapadia has no financial relationships to disclose.
    • Peter Mannon, MD, AGA Reviewer has a consulting fee – speaker/teaching with AbbVie, consulting fee - consulting with Vitaris.
    • Chad Burski, MD, AGA Reviewer has stock ownership interest with the following companies, AstraZeneca, Johnson & Johnson, Kimberly Clark, Merck, and Proctor and Gamble. 
  • Learning Objectives

     After participating in this educational activity, participants should be better able to:

    • Describe the role of treat-to-target strategies in improving long-term outcomes in patients with IBD
    • Formulate treatment adjustments in patients who have become nonresponsive, experience diminished response, or become refractory to initial treatment for IBD
  • Target Audience

    This activity is designed to meet the primary educational needs of community gastroenterologists and the secondary educational needs of primary care physicians.

  • Accreditation and Credit Designation Statements

    The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The AGA Institute designates this activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    The American Gastroenterological Association is the trusted voice of the GI community. AGA’s educational programs engage professionals through multiple platforms that support all learning styles. Ranging from research protocols that help inform behavioral change to self-administered training modules, AGA’s educational initiatives arm gastroenterologists and other members of the GI healthcare team with the tools needed to provide high-quality, efficient care.

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie Inc., Bristol Myers Squibb, and Takeda Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Neilanjan Nandi, MD, FACP, AGAF
    Associate Professor of Clinical Medicine
    University of Pennsylvania
    Penn Presbyterian Medical Center
    Philadelphia, PA 

    Consulting Fees: Forefront,Pfizer

    Faculty:
    Gary R. Lichtenstein, MD, FACG, FACP, AGAF
    Professor of Medicine
    Director, Center for Inflammatory Bowel Disease
    University of Pennsylvania Health System
    Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 

    Consulting Fees: AbbVie, American Regent, Celgene, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Ortho Biotech, Merck, Morphic Therapeutic, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, and UCB
    Contracted Research: Celgene, Janssen Ortho Biotech, and UCB; served on the DSMB for Eli Lilly
    Received Honoraria (CME program): American Regent, Merck, and Romark
    Received Funding to the University of Pennsylvania (IBD fellow education): Janssen Ortho Biotech, Pfizer Pharmaceuticals, and Takeda.

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Colleen Resnick has nothing to disclose.
    • Poonam Kapadia has no financial relationships to disclose.
    • Peter Mannon, MD, AGA Reviewer has a consulting fee – speaker/teaching with AbbVie, consulting fee - consulting with Vitaris.
    • Chad Burski, MD, AGA Reviewer has stock ownership interest with the following companies, AstraZeneca, Johnson & Johnson, Kimberly Clark, Merck, and Proctor and Gamble. 
  • Learning Objectives

     After participating in this educational activity, participants should be better able to:

    • Describe the role of treat-to-target strategies in improving long-term outcomes in patients with IBD
    • Formulate treatment adjustments in patients who have become nonresponsive, experience diminished response, or become refractory to initial treatment for IBD
  • Target Audience

    This activity is designed to meet the primary educational needs of community gastroenterologists and the secondary educational needs of primary care physicians.

  • Accreditation and Credit Designation Statements

    The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The AGA Institute designates this activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    The American Gastroenterological Association is the trusted voice of the GI community. AGA’s educational programs engage professionals through multiple platforms that support all learning styles. Ranging from research protocols that help inform behavioral change to self-administered training modules, AGA’s educational initiatives arm gastroenterologists and other members of the GI healthcare team with the tools needed to provide high-quality, efficient care.

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie Inc., Bristol Myers Squibb, and Takeda Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 5/11/21